Skip to main content

Scholar Rock Holding Corp(SRRK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low44.88
Day High46.52
Open:44.91
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Scholar Rock Holding Corp

Select a category then submit the form to load news
Tipranks
Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Alcon (ALC)
Tipranks
Bank of America Securities Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)
Tipranks
Barclays Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)
Tipranks
Scholar Rock Advances Apitegromab Toward SMA Commercial Launch
Motley Fool
Scholar Rock (SRRK) Q4 2025 Earnings Transcript
Tipranks
Scholar Rock’s New FORGE Study Puts Apitegromab to the Test in FSHD
Motley Fool
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
Motley Fool
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Motley Fool
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
Motley Fool
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK) and Standard BioTools (LAB)
Tipranks
Bank of America Securities Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Tipranks
Raymond James Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Tipranks
Scholar Rock Details 2026 Strategy and Regulatory Priorities
Tipranks
Scholar Rock Holding (SRRK) Receives a Buy from Barclays
Tipranks
Analysts Offer Insights on Healthcare Companies: Novan (NOVN), Pelthos Therapeutics (PTHS) and Scholar Rock Holding (SRRK)
Motley Fool
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
Tipranks
Scholar Rock Faces FDA Warning, Plans 2026 Launch
Tipranks
Analysts’ Top Healthcare Picks: Hinge Health, Inc. Class A (HNGE), Scholar Rock Holding (SRRK)
Business Wire
Scholar Rock to Present at Upcoming Investor Conferences
Tipranks
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Zimmer Biomet Holdings (ZBH) and Hinge Health, Inc. Class A (HNGE)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Scholar Rock’s Earnings Call: Optimism Amid Regulatory Challenges
Tipranks
Scholar Rock Advances SMA Treatment Amid Financial Losses
Tipranks
Scholar Rock Announces $200M At-The-Market Offering
Tipranks
Scholar Rock Holds Constructive FDA Meeting for Apitegromab
Business Wire
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MarketBeat
3 Beaten-Down Stocks With Rebound Potential This Earnings Season

Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.